Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial

IMPORTANCE: Myelofibrosis is a hematologic malignancy characterized by splenomegaly and debilitating symptoms. Thrombocytopenia is a poor prognostic feature and limits use of Janus kinase 1 (JAK1)/Janus kinase 2 (JAK2) inhibitor ruxolitinib. OBJECTIVE: To compare the efficacy and safety of JAK2 inhi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:JAMA Oncol
Autors principals: Mascarenhas, John, Hoffman, Ronald, Talpaz, Moshe, Gerds, Aaron T., Stein, Brady, Gupta, Vikas, Szoke, Anita, Drummond, Mark, Pristupa, Alexander, Granston, Tanya, Daly, Robert, Al-Fayoumi, Suliman, Callahan, Jennifer A., Singer, Jack W., Gotlib, Jason, Jamieson, Catriona, Harrison, Claire, Mesa, Ruben, Verstovsek, Srdan
Format: Artigo
Idioma:Inglês
Publicat: American Medical Association 2018
Matèries:
Original Investigation
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5885169/
https://ncbi.nlm.nih.gov/pubmed/29522138
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2017.5818
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars